Changeflow GovPing Healthcare & Life Sciences Periosteal Distraction With Skin Grafting for D...
Routine Notice Added Final

Periosteal Distraction With Skin Grafting for DFU, 104-Patient Randomized Trial

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

A single-center, prospective, randomized controlled trial registered on ClinicalTrials.gov (NCT07545668) will evaluate whether periosteal distraction combined with autologous split-thickness skin grafting improves graft survival at postoperative day 14 compared with skin grafting alone in 104 patients with diabetic foot ulcers (Wagner grade 2-3 or post-amputation). Participants are randomized 1:1 into experimental (n=52) and control (n=52) groups, with secondary outcomes including time to complete epithelialization, wound healing quality (BWAT score at 3 months), ulcer recurrence at 6 months, foot function (AOFAS score), quality of life (DFS-SF score), and safety profile. The study addresses poor graft survival in ischemic wound environments and aims to establish a novel minimally invasive treatment paradigm for diabetic foot ulcers.

“A total of 104 eligible patients will be randomly assigned to either the experimental group (periosteal distraction + skin grafting, n=52) or the control group (skin grafting alone, n=52).”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 715 changes logged to date.

What changed

This document registers a new randomized controlled trial (NCT07545668) on ClinicalTrials.gov evaluating periosteal distraction combined with skin grafting for diabetic foot ulcers. The trial will enroll 104 eligible patients randomized equally between experimental and control groups, studying graft survival as the primary outcome at postoperative day 14.

For healthcare providers and clinical researchers, this trial registration signals emerging evidence development in ischemic wound management for diabetic foot ulcers. While the registration itself does not create compliance obligations, it may inform future clinical practice guidelines and represents an area of active investigation for treatment-refractory wounds.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Periosteal Distraction With Skin Grafting for DFU

N/A NCT07545668 Kind: NA Apr 22, 2026

Abstract

This study is a single-center, prospective, randomized controlled trial aimed at evaluating whether periosteal distraction combined with autologous split-thickness skin grafting can significantly improve graft survival rate at postoperative day 14 compared with skin grafting alone in patients with diabetic foot ulcers (Wagner grade 2-3 or post-amputation). A total of 104 eligible patients will be randomly assigned to either the experimental group (periosteal distraction + skin grafting, n=52) or the control group (skin grafting alone, n=52). Secondary outcomes include time to complete epithelialization, wound healing quality (BWAT score at 3 months), ulcer recurrence rate (at 6 months), foot function (AOFAS score), quality of life (DFS-SF score), and safety profile. This study aims to address the critical clinical bottleneck of poor graft survival in ischemic wound environments, providing a novel, minimally invasive, and synergistic treatment paradigm for diabetic foot ulcers.

Conditions: Diabetic Foot Disease, Wound Healing

Interventions: Periosteal Distraction, Skin Grafting

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 22nd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Diabetic wound care Surgical research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!